{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:04:46Z","timestamp":1789452286339,"version":"build-2803163510"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>To describe the clinical outcomes of transitioning from efgartigimod to tacrolimus in chronic inflammatory demyelinating polyneuropathy (CIDP) patients. Six patients who completed the ADHERE trial and maintained clinical stability during the open-label extension phase (\u226530 weeks of weekly efgartigimod) were transitioned to oral tacrolimus following efgartigimod discontinuation and were followed at 3-month intervals for 12 months. Clinical effectiveness was assessed utilizing the Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale, centile Inflammatory Rasch-built Overall Disability Scale (cI-RODS), Medical Research Council (MRC) sum score (0-60), grip strength, 3m-Timed Up and Go Test (TUG) as well as electrophysiological examination. Safety was evaluated by monitoring adverse events. Peripheral T and B lymphocytes, interleukins and immunoglobulin levels were measured at each visit, and tacrolimus trough levels were monitored during follow-up. Three of six patients completed 12-month follow-up and achieved clinical stability or improvement by month 12. Two discontinued within three months due to poor clinical response and regained improvement following transition back to intravenous immunoglobulin or efgartigimod. One expressed a preference for traditional Chinese medicine and was lost to follow-up. No severe adverse events were observed. Oral tacrolimus may be a potential maintenance approach for sustaining clinical stability in a subset of CIDP patients stabilized on efgartigimod. Longitudinal naive B-cell monitoring warrants further investigation as a potential early indicator of clinical instability during tacrolimus maintenance therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1916815","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:36:32Z","timestamp":1789450592000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Transitioning from efgartigimod to tacrolimus in chronic inflammatory demyelinating polyneuropathy: a prospective case series"],"prefix":"10.3389","volume":"17","author":[{"given":"Yujia","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]},{"name":"Huashan Rare Disease Center, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianian","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]},{"name":"Huashan Rare Disease Center, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]},{"name":"Huashan Rare Disease Center, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]},{"name":"Huashan Rare Disease Center, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heting","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]},{"name":"Huashan Rare Disease Center, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]},{"name":"Huashan Rare Disease Center, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]},{"name":"Huashan Rare Disease Center, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]},{"name":"Huashan Rare Disease Center, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]},{"name":"Huashan Rare Disease Center, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]},{"name":"Huashan Rare Disease Center, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"National Center for Neurological Disorders, Fudan University","place":["Shanghai, China"]},{"name":"Huashan Rare Disease Center, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12455","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-second revision","volume":"26","author":"Van den Bergh","year":"2021","journal-title":"J Peripher Nerv Syst"},{"key":"B2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/jnnp-2024-334165","article-title":"Novel therapies in CIDP","volume":"96","author":"Mair","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"Lancet Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309697","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype","volume":"86","author":"Mathey","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1331800","article-title":"Mechanism of tacrolimus in the treatment of lupus nephritis","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/mus.70025","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) developing during tacrolimus treatment: a case series","volume":"72","author":"Evans","year":"2025","journal-title":"Muscle Nerve"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S536989","article-title":"Efficacy of tacrolimus plus prednisone as long-term immunosuppressive therapy for chronic inflammatory demyelinating polyneuropathy: a retrospective cohort study","volume":"14","author":"Di","year":"2025","journal-title":"Immunotargets Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i5.1709","article-title":"Tacrolimus treatment for relapsing-remitting chronic inflammatory demyelinating polyradiculoneuropathy: two case reports","volume":"10","author":"Zhu","year":"2022","journal-title":"World J Clin cases"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11759-2","article-title":"Effectiveness and safety of rituximab in autoimmune nodopathy: a single-center cohort study","volume":"270","author":"Liu","year":"2023","journal-title":"J Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241110-00003","article-title":"Mechanisms of clinically relevant drug interactions associated with tacrolimus","volume":"41","author":"Christians","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51312","article-title":"In-depth peripheral CD4+ T profile correlates with myasthenic crisis","volume":"8","author":"Huan","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1575464","article-title":"A pathophysiological and mechanistic review of chronic inflammatory demyelinating polyradiculoneuropathy therapy","volume":"16","author":"Caballero-\u00c1vila","year":"2025","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2022.2104261","article-title":"Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis","volume":"55","author":"Guptill","year":"2022","journal-title":"Autoimmunity"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13189","article-title":"Adequate tacrolimus concentration for myasthenia gravis treatment","volume":"24","author":"Kanai","year":"2017","journal-title":"Eur J Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.577139","article-title":"Unique HLA haplotype associations in IgG4 anti-neurofascin 155 antibody-positive chronic inflammatory demyelinating polyneuropathy","volume":"339","author":"Ogata","year":"2020","journal-title":"J Neuroimmunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4137\/pmc.s382","article-title":"Effects of FK506 on Ca release channels (review)","volume":"2","author":"Ozawa","year":"2008","journal-title":"Perspect Medicin Chem"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199809000-00020","article-title":"Treatment of normal skeletal muscle with FK506 or rapamycin results in halothane-induced muscle contracture","volume":"89","author":"Brooksbank","year":"1998","journal-title":"Anesthesiology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1916815\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:36:32Z","timestamp":1789450592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1916815\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":17,"alternative-id":["10.3389\/fimmu.2026.1916815"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1916815","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1916815"}}